Phenytin® (Phenytoin): Dosing, Formulations & Critical Safety Warnings

Disclaimer

We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. By using this blog, you agree to assume personal responsibility for relying on the information provided.

The information below is intended for educational and informational purposes only and does not replace the prescribing information, professional medical judgment, or individualized advice from a qualified healthcare professional. Phenytoin is a narrow-therapeutic-index antiseizure medication with clinically important drug interactions and potentially serious adverse effects. Dosing, formulation changes, therapeutic drug monitoring, and parenteral administration should therefore be managed by appropriately qualified healthcare professionals.

Summary

Phenytin® is a phenytoin-containing antiseizure medication manufactured by The NILE Co. for Pharmaceuticals and Chemical Industries, Cairo, Egypt. The supplied product information describes capsules, oral suspension, and injectable ampoules containing phenytoin sodium or phenytoin free acid depending on the formulation.

Phenytoin is a hydantoin derivative antiseizure medication that primarily suppresses high-frequency repetitive neuronal firing by blocking voltage-gated sodium channels. It is used principally for generalized tonic-clonic seizures and focal seizures with impaired awareness (historically called complex partial seizures) and has an established parenteral role in the treatment of generalized convulsive status epilepticus and seizures associated with neurosurgery.

Phenytoin has a narrow therapeutic index, extensive protein binding, nonlinear saturable metabolism, and a large potential for clinically important drug interactions. Consequently, relatively small dosage changes can sometimes produce disproportionately large changes in serum concentrations. Therapeutic drug monitoring is particularly important when doses are changed, formulations are switched, interacting drugs are introduced or withdrawn, or renal/hepatic dysfunction or hypoalbuminemia is present.

Intravenous phenytoin requires particular caution because rapid administration can cause severe hypotension, bradycardia, and cardiac arrhythmias. Peripheral intravenous administration can also cause serious local tissue injury, including purple glove syndrome.

Brand Name

Phenytin®

Arabic brand name: فينيـتين

The supplied Egyptian product information identifies Phenytin as a product containing phenytoin and lists multiple formulations and strengths.

Category

• Antiseizure medication (antiepileptic / anticonvulsant)
• Hydantoin derivative
• Pharmacological class: Voltage-gated sodium-channel blocker

Active Ingredient

Phenytin formulations contain phenytoin, either as:

• Phenytoin sodium — used in the capsules and injectable formulation described in the supplied product information.
• Phenytoin free acid — used in the micronized oral suspension.

The distinction between phenytoin sodium and phenytoin free acid is clinically important because the free-acid formulation contains approximately 8% more phenytoin per equivalent labeled amount than the sodium-salt formulation. Switching formulations should therefore not be performed casually and may require dose adjustment and serum-level monitoring.

Pharmaceutical Form & Strength

According to the supplied Phenytin product information, the product is available in the following dosage forms and strengths:

1. Phenytin 50 mg Capsules

• 50 mg phenytoin sodium per capsule.
• Pack: 50 capsules.
• Listed inactive ingredients:
  • PEG 6000
  • Lactose
  • Magnesium stearate
  • Sodium starch glycolate

2. Phenytin 100 mg Capsules

• 100 mg phenytoin sodium per capsule.
• Pack: 50 capsules.
• Listed inactive ingredients:
  • PEG 6000
  • Lactose
  • Magnesium stearate
  • Sodium starch glycolate

3. Phenytin 30 mg/5 mL Oral Suspension

• 30 mg phenytoin per 5 mL.
• Pack: 120 mL.
• The supplied information identifies this as micronized phenytoin free acid.
• Listed inactive ingredients:
  • Sodium benzoate
  • Citric acid
  • Glycerin
  • Polysorbate 60
  • Sucrose
  • Ethyl alcohol
  • Banana flavor
  • Vanillin
  • Orange oil
  • Carmoisine
  • Sunset Yellow

4. Phenytin 100 mg/2 mL Ampoule

• 50 mg phenytoin sodium per mL.
• Total: 100 mg per 2 mL ampoule.
• Listed inactive ingredients:
  • Propylene glycol
  • Ethyl alcohol
  • Sodium hydroxide

5. Phenytin 250 mg/5 mL Ampoule

• 50 mg phenytoin sodium per mL.
• Total: 250 mg per 5 mL ampoule.
• Listed inactive ingredients:
  • Propylene glycol
  • Ethyl alcohol
  • Sodium hydroxide

The original supplied document also lists packaging configurations of 1 or 10 ampoules for some presentations and 100 ampoules for the 250 mg/5 mL presentation.

Manufacturer & Marketing Authorization Holder

Manufacturer:

The NILE Co. for Pharmaceuticals and Chemical Industries

Cairo, Arab Republic of Egypt.

The supplied historical product document identifies the manufacturer as The NILE Co. for Pharmaceuticals and Chemical Industries and gives the registered Chamber of Commerce number as R.C.C. 115668.

The document supplied does not provide sufficiently current regulatory evidence to independently establish the present-day marketing-authorization-holder status separately from the manufacturer. Therefore, the manufacturer information above is retained, while current Egyptian regulatory registration should be verified against the latest official Egyptian regulatory records before publication or commercial use.

Mechanism of Action

Phenytoin is a membrane-stabilizing antiseizure medication whose principal mechanism is blockade of voltage-gated sodium channels.

It preferentially binds to and stabilizes the inactivated state of voltage-gated sodium channels. This reduces the ability of neurons to generate high-frequency repetitive action potentials and thereby limits the initiation and spread of abnormal electrical activity.

In practical terms:

1. Excessively active neurons repeatedly open voltage-gated sodium channels.
2. Phenytoin preferentially stabilizes sodium channels in their inactive state.
3. Recovery of the channels is slowed.
4. High-frequency repetitive neuronal firing is suppressed.
5. Propagation of seizure activity through cortical neuronal networks is reduced.

The older supplied document describes the action as "promoting sodium efflux from neurons." That wording is not an accurate modern description of phenytoin's principal mechanism and has therefore been replaced by the established voltage-gated sodium-channel mechanism.

Phenytoin reduces seizure propagation without simply producing generalized neuronal suppression; its activity is particularly associated with limiting repetitive high-frequency firing.

Spectrum of Activity

Phenytoin is primarily effective against:

• Generalized tonic-clonic seizures
• Focal seizures, including focal seizures historically described as:
  • complex partial seizures
  • psychomotor seizures
  • temporal-lobe seizures

It is not an appropriate treatment for typical absence seizures and may worsen some generalized seizure types. Therefore, seizure classification is important before selecting phenytoin as long-term antiseizure therapy.

The supplied product information specifically states that Phenytin is not effective for absence (petit mal) seizures.

For generalized convulsive status epilepticus, current clinical practice generally uses a benzodiazepine as initial emergency therapy, followed when necessary by an appropriate second-line antiseizure medication. Current NICE guidance recognizes intravenous levetiracetam, phenytoin, and valproate as options after two doses of a benzodiazepine, while noting practical advantages and potentially fewer adverse effects with levetiracetam.

Pharmacokinetics

Absorption

Following oral administration, phenytoin is slowly but substantially absorbed.

The exact bioavailability varies with formulation and product. Phenytoin sodium capsules have high oral bioavailability, whereas formulation differences can meaningfully influence exposure.

Because phenytoin concentrations are highly sensitive to dosage and formulation changes, patients should avoid switching between different formulations or brands without appropriate clinical supervision.

Distribution

Phenytoin is approximately 90% protein bound, principally to serum albumin.

Only the unbound fraction is pharmacologically active and capable of readily crossing biological membranes, including the blood-brain barrier.

The clinically relevant consequence is that patients with:

• hypoalbuminemia,
• renal disease,
• hepatic disease,
• severe systemic illness,

may have an increased free fraction despite an apparently acceptable total serum phenytoin concentration.

In such circumstances, unbound phenytoin concentration may be more clinically informative than total concentration.

Metabolism

Phenytoin is extensively metabolized in the liver, principally through CYP2C9 and CYP2C19.

A major pharmacokinetic characteristic is capacity-limited, nonlinear (saturable) metabolism.

At lower concentrations, metabolism behaves approximately according to first-order kinetics. As metabolic pathways become saturated, however, small increases in dose can produce disproportionately large increases in serum concentration.

This is one of the principal reasons why phenytoin requires careful dose titration and therapeutic drug monitoring.

Half-Life

The mean adult plasma half-life after oral administration is approximately 22 hours, but substantial interindividual variation occurs.

The effective half-life can increase considerably as metabolic pathways become saturated.

Children generally have faster clearance than adults and may therefore require different weight-based dosing and more frequent individualized adjustment.

Steady State

With regular dosing, approximately 7–10 days may be required to reach a new steady-state concentration.

Therefore, routine dosage adjustments should generally not be made too frequently unless the clinical situation requires urgent intervention.

Elimination

Phenytoin is metabolized mainly in the liver to inactive metabolites. These metabolites are subsequently eliminated predominantly through the urine.

Indications

Phenytin/phenytoin may be used for:

1. Control of generalized tonic-clonic seizures.
2. Control of focal seizures, including focal impaired-awareness seizures.
3. Prevention and treatment of seizures associated with neurosurgery.
4. Treatment of generalized convulsive status epilepticus using the parenteral formulation.
5. Short-term substitution for oral phenytoin when oral administration is not possible, when clinically appropriate.

The exact indication depends on seizure type, patient characteristics, comorbidities, concomitant medications, and current epilepsy-management guidelines.

Administration

Phenytoin has a narrow therapeutic index, so dosing should be individualized.

Therapeutic Drug Monitoring

A commonly used therapeutic range for total serum phenytoin concentration is:

10–20 mcg/mL (10–20 mg/L)

An unbound concentration of approximately 1–2 mcg/mL is often considered the corresponding therapeutic range.

However, serum concentrations must always be interpreted together with the clinical response, because some patients achieve seizure control at concentrations below the conventional total range. In patients with hypoalbuminemia or renal/hepatic disease, measurement of the unbound concentration may be more useful.

Oral Administration — Capsules and Suspension

The historical Phenytin leaflet supplied with the source document describes:

Adults

For previously untreated patients:

• 300 mg/day, divided into three doses.
• The dose may be increased by 100 mg/day at weekly intervals when clinically indicated.
• Typical maintenance dosing is described as approximately 300–400 mg/day.

However, modern prescribing information emphasizes individualized dosing and therapeutic drug monitoring rather than relying on a universal fixed maintenance regimen.

Pediatric Patients

The supplied document describes:

• Initial dose: approximately 5 mg/kg/day, divided into 2 or 3 doses.
• Maintenance dose: generally 4–8 mg/kg/day, individualized according to clinical response and serum concentrations.
• Maximum doses depend on the specific product, age, and clinical circumstances.

Current product labeling similarly describes an initial pediatric dose of approximately 5 mg/kg/day followed by individualized adjustment.

Important Formulation Consideration

The oral suspension contains phenytoin free acid, whereas extended-release phenytoin capsules generally contain phenytoin sodium.

Because the free-acid formulation provides approximately 8% more phenytoin content than the equivalent labeled amount of the sodium salt, switching between these formulations can alter serum concentrations. Dose adjustment and therapeutic drug monitoring may therefore be required.

Parenteral Administration

Intravenous Loading

For generalized convulsive status epilepticus or other situations requiring parenteral loading:

Adults

A commonly used intravenous loading dose is:

10–15 mg/kg

depending on the clinical protocol and indication.

Some contemporary protocols may use higher loading doses in selected circumstances, but dosing must follow the applicable institutional/emergency protocol and product information.

Children

A typical intravenous loading dose is:

15–20 mg/kg

administered under continuous monitoring.

Maximum Intravenous Administration Rate

The intravenous administration rate must not exceed 50 mg/minute in adults.

For pediatric patients, the rate should not exceed:

1–3 mg/kg/minute or 50 mg/minute, whichever is slower.

Continuous monitoring of:

• ECG,
• blood pressure,
• respiratory status,

is required during and immediately following intravenous administration because severe hypotension and cardiac arrhythmias can occur.

The older supplied document correctly emphasizes continuous ECG, blood-pressure, and respiratory monitoring during intravenous administration, but its older dosing language should not be used as a substitute for current institutional protocols.

Method of Preparation — Intravenous Administration

Phenytoin sodium injection is highly alkaline and has poor solubility at lower pH.

Do NOT dilute with dextrose-containing solutions

Phenytoin sodium injection should not be mixed or diluted with dextrose-containing solutions such as D5W, because precipitation may occur.

Compatible diluent

When dilution is required, 0.9% sodium chloride (normal saline) should be used.

The current labeling specifies that the final concentration for infusion should be no less than 5 mg/mL, and administration should begin promptly after preparation. An appropriate in-line filter should be used.

Intravenous line

Because of the alkalinity and local toxicity of injectable phenytoin:

• Use a suitable large vein and appropriate catheter.
• Confirm catheter patency with sterile saline before administration.
• Flush with normal saline after administration.
• Monitor the injection site carefully.

Intramuscular Administration

The historical Phenytin document describes intramuscular administration during neurosurgery, including 100–200 mg at approximately 4-hour intervals.

However, this information is not consistent with modern practice.

Intramuscular phenytoin is generally discouraged because absorption can be erratic and delayed and significant local tissue injury can occur. Current labeling states that injectable phenytoin should ordinarily not be administered intramuscularly because of erratic absorption and local toxicity.

Therefore, the historical IM regimen should not be presented as a routine modern administration strategy.

Contraindications

Phenytoin is contraindicated in patients with:

• Known hypersensitivity to phenytoin.
• Hypersensitivity to other hydantoins or relevant formulation excipients.
• Sinus bradycardia.
• Sinoatrial block.
• Second-degree or third-degree atrioventricular block.
• Adams–Stokes syndrome.
• A history of clinically significant acute hepatotoxicity attributable to phenytoin.

For injectable formulations, the cardiovascular contraindications are particularly important because of the potential for conduction abnormalities and severe cardiovascular reactions.

Warnings & Precautions

1. Cardiovascular Toxicity with Intravenous Administration

Rapid intravenous administration can cause:

• severe hypotension,
• bradycardia,
• cardiac arrhythmias,
• cardiovascular collapse.

These events can occur even at or below the recommended infusion rate, so careful monitoring remains essential.

2. Purple Glove Syndrome

Peripheral intravenous phenytoin can cause purple glove syndrome, characterized by:

• pain,
• edema,
• bluish-purple discoloration,
• tissue injury distal to the injection site.

Severe cases may progress to:

• skin necrosis,
• ischemia,
• compartment-type complications,
• and, rarely, limb-threatening injury requiring surgical intervention or amputation.

3. Serious Cutaneous Adverse Reactions

Phenytoin can cause serious and potentially life-threatening cutaneous adverse reactions, including:

• Stevens–Johnson syndrome (SJS),
• toxic epidermal necrolysis (TEN),
• drug reaction with eosinophilia and systemic symptoms (DRESS),
• other severe cutaneous adverse reactions.

Patients should seek urgent medical assessment if they develop a new significant rash, particularly when accompanied by:

• fever,
• facial edema,
• mucosal lesions,
• blistering,
• skin pain,
• systemic symptoms.

HLA-B*1502 is associated with an increased risk of SJS/TEN in certain Asian populations taking phenytoin. Pharmacogenomic information should therefore be considered according to ancestry and applicable prescribing guidance.

4. Abrupt Withdrawal

Phenytoin should not be stopped abruptly without medical supervision.

Sudden withdrawal can precipitate breakthrough seizures and, in susceptible patients, potentially life-threatening status epilepticus.

Dose reduction or discontinuation should generally be performed under specialist supervision.

5. Hepatic Dysfunction

The liver is the principal site of phenytoin metabolism.

Patients with hepatic impairment may have reduced clearance and increased exposure and may develop toxicity at doses previously tolerated.

6. Renal Disease and Hypoalbuminemia

Because phenytoin is highly protein bound, renal disease, hepatic disease, and hypoalbuminemia can increase the unbound active fraction.

A patient may therefore have a seemingly acceptable total serum concentration while having an excessive pharmacologically active free concentration.

In these circumstances, unbound phenytoin monitoring is preferable when available.

7. Elderly Patients

Phenytoin clearance may decrease with increasing age.

Older patients may therefore require lower or less frequent dosing and closer monitoring.

8. Hyperglycemia

Phenytoin may increase blood glucose concentrations, including through effects on insulin secretion.

Patients with diabetes or impaired glucose regulation may therefore require appropriate monitoring.

9. Suicidal Thoughts and Behavioral Changes

As with other antiseizure medications, patients receiving phenytoin should be monitored for:

• depression,
• significant mood changes,
• suicidal thoughts or behavior.

Any concerning psychiatric change requires prompt clinical assessment.

10. Oral Health and Gingival Hyperplasia

Long-term phenytoin treatment is strongly associated with gingival overgrowth (gingival hyperplasia).

Good oral hygiene and regular dental assessment are important preventive measures.

The risk is particularly important in children and in patients with inadequate oral hygiene.

11. Neurological Toxicity

Dose-related toxicity may produce:

• nystagmus,
• ataxia,
• slurred speech,
• dizziness,
• impaired coordination,
• confusion,
• headache.

These findings may indicate excessive serum exposure and should prompt clinical assessment and, when appropriate, measurement of serum phenytoin concentration.

Drug Interactions

Phenytoin is a major source of drug interactions because it is both a substrate of hepatic CYP enzymes and a potent enzyme inducer, particularly affecting CYP3A4, CYP2C9, CYP2C19 and UGT pathways.

It can therefore reduce the concentrations and effectiveness of many concurrently administered medications.

Important interactions include:

Drugs that may increase phenytoin concentrations

Examples include:

• amiodarone,
• chloramphenicol,
• cimetidine and some H2-receptor antagonists,
• diazepam,
• disulfiram,
• estrogens,
• sulfonamides,
• some salicylates,
• and other CYP-inhibiting medicines.

The exact effect varies according to the individual drug and clinical context.

Drugs whose effectiveness may be reduced by phenytoin

Phenytoin enzyme induction can reduce exposure to several medications, including:

• oral hormonal contraceptives,
• warfarin and other drugs whose metabolism is affected by enzyme induction,
• corticosteroids,
• digitoxin,
• certain immunosuppressants,
• and other CYP/UGT substrates.

Therefore, patients taking phenytoin should have medication interactions reviewed whenever another prescription, over-the-counter medicine, supplement, or herbal product is started or discontinued.

Alcohol

Alcohol can have different effects depending on the pattern of consumption.

• Acute alcohol intake may increase phenytoin concentrations.
• Chronic alcohol use can increase phenytoin metabolism and decrease concentrations.

Therefore, alcohol consumption may make serum phenytoin concentrations unpredictable.

Vitamin D and Bone Health

The historical supplied document lists vitamin D among substances that may increase phenytoin concentrations.

This statement should not be presented as a routine modern interaction without qualification.

A more clinically relevant long-term issue is that enzyme-inducing antiseizure medications such as phenytoin can increase vitamin D metabolism and contribute to reduced bone mineral density and osteomalacia/osteoporosis risk. Patients receiving long-term therapy may therefore require assessment of bone health and vitamin D status according to their individual risk factors and local clinical guidance.

Side Effects

Common or Dose-Related Neurological Effects

• Nystagmus
• Ataxia
• Slurred speech
• Dizziness
• Impaired coordination
• Confusion
• Headache

These effects are often associated with excessive serum concentrations.

Gastrointestinal Effects

• Nausea
• Vomiting
• Constipation
• Hepatotoxicity
• Toxic hepatitis
• Liver injury

Dermatological Effects

• Rash
• Exfoliative dermatitis
• SJS
• TEN
• DRESS and other serious cutaneous adverse reactions

Gingival Effects

• Gingival enlargement
• Gingival hyperplasia

Good oral hygiene and regular dental care are particularly important.

Hematological Effects

Potential hematological adverse effects include:

• thrombocytopenia,
• leukopenia,
• granulocytopenia,
• agranulocytosis,
• macrocytosis,
• megaloblastic anemia.

Phenytoin may interfere with folate metabolism and contribute to folate-related hematological abnormalities.

Peripheral Neuropathy

Long-term therapy has been associated with predominantly sensory peripheral polyneuropathy.

Immunological Effects

Immunoglobulin abnormalities, including reductions in immunoglobulin levels, have been reported.

Serious Adverse Effects Requiring Urgent Attention

Immediate medical assessment is warranted for:

• severe or rapidly spreading rash,
• blistering,
• mucosal ulceration,
• facial edema,
• fever with rash,
• jaundice,
• severe abdominal symptoms,
• unexplained bruising or bleeding,
• severe weakness,
• significant gait disturbance,
• marked confusion,
• fainting,
• severe hypotension,
• abnormal heart rhythm,
• or severe pain/swelling/discoloration at an intravenous injection site.

Use in Special Populations

Pregnancy

Phenytoin crosses the placenta and is associated with fetal risks, including congenital malformations and the characteristic fetal hydantoin syndrome.

Reported abnormalities may include:

• craniofacial abnormalities,
• cleft lip/palate,
• limb abnormalities,
• cardiovascular abnormalities,
• growth abnormalities,
• and other developmental effects.

However, uncontrolled maternal seizures can themselves cause substantial maternal and fetal harm.

Therefore:

• phenytoin should not be stopped abruptly during pregnancy;
• treatment decisions require an individualized risk-benefit assessment;
• the lowest effective dose should be used when phenytoin remains clinically necessary;
• serum concentrations may change during pregnancy and should be monitored appropriately;
• because protein binding can change during pregnancy, unbound concentrations may be particularly informative.

Current product labeling specifically notes that serum phenytoin concentrations can decrease during pregnancy and recommends periodic monitoring with dose adjustment when necessary.

Vitamin K and the Newborn

In-utero exposure to enzyme-inducing antiseizure medications including phenytoin has been associated with a risk of neonatal bleeding due to reduced vitamin-K-dependent clotting factors.

Vitamin K administration to the mother before delivery and vitamin K administration to the newborn after birth are described in product labeling as measures to reduce this risk.

The exact obstetric and neonatal strategy should follow current obstetric and neonatal guidance.

Lactation

Phenytoin is excreted into human breast milk in relatively small amounts.

Breastfeeding decisions should balance:

• the mother's need for seizure control,
• the benefits of breastfeeding,
• the infant's potential exposure,
• and the infant's clinical condition.

Infants should be monitored for:

• poor feeding,
• excessive sleepiness,
• inadequate weight gain,
• or other concerning symptoms.

Current product labeling confirms that phenytoin is secreted into human milk and recommends consideration of the benefits of breastfeeding against the mother's clinical need and potential infant effects.

Pediatric Use

Children may clear phenytoin more rapidly than adults.

Consequently:

• weight-based dosing is important;
• serum concentrations may require monitoring;
• doses should be individualized;
• children require particular attention to oral hygiene because of the risk of gingival hyperplasia.

Geriatric Use

Older adults may have:

• reduced hepatic clearance,
• lower albumin concentrations,
• increased free phenytoin fraction,
• increased susceptibility to neurological toxicity.

Lower starting doses and slower individualized titration may therefore be appropriate.

Renal and Hepatic Impairment

Patients with renal or hepatic disease may have an increased unbound fraction of phenytoin.

In such patients, total serum concentration may underestimate pharmacologically active exposure.

Monitoring of unbound phenytoin concentration, where available, is therefore particularly valuable.

Storage Conditions

According to the supplied Phenytin product information:

Capsules

• Store below 25°C.
• Keep in the original tightly closed container.

Oral Suspension

• Store below 30°C.
• Keep the bottle tightly closed.

Ampoules

• Store below 30°C.
• Protect from inappropriate storage conditions.
• Inspect the solution before administration.
• Do not administer a solution showing inappropriate discoloration or visible particles/crystals.

The supplied product document specifies storage below 25°C for capsules and below 30°C for suspension and ampoules.

For injectable phenytoin, current labeling also emphasizes inspection for particulate matter or discoloration before administration and appropriate handling of precipitate formation.

Additional Sections

Patient Instructions

1. Maintain consistency of formulation

Patients should not switch between phenytoin brands or formulations without medical supervision.

This is particularly important when switching between:

• phenytoin sodium,
• phenytoin free acid,
• capsules,
• and oral suspension.

Such changes can alter serum exposure and may require therapeutic drug monitoring.

2. Take consistently with respect to food

The historical Phenytin instructions advise taking the oral medicine with food or milk to reduce gastrointestinal discomfort.

More importantly, patients should maintain a consistent administration pattern and follow the specific product instructions because food and formulation differences can influence phenytoin absorption.

3. Maintain meticulous oral hygiene

Patients should:

• brush regularly,
• floss,
• maintain dental hygiene,
• attend regular dental check-ups.

This helps reduce the risk and severity of gingival hyperplasia.

4. Never stop suddenly

Do not discontinue phenytoin abruptly unless specifically instructed by a healthcare professional.

5. Avoid or minimize alcohol

Alcohol can alter phenytoin concentrations and may also worsen CNS adverse effects.

6. Driving and hazardous activities

Patients should use caution when driving or performing activities requiring:

• alertness,
• coordination,
• rapid reaction,
• physical dexterity,

until they know how phenytoin affects them.

Frequently Asked Questions (FAQ)

Q1. Can Phenytin injection be diluted with D5W?

No.

Phenytoin sodium injection should not be diluted with dextrose-containing solutions such as D5W because precipitation can occur.

If dilution is required, 0.9% sodium chloride (normal saline) should be used according to the applicable product instructions and institutional protocol.

Q2. What is Purple Glove Syndrome?

Purple glove syndrome is a serious local complication of peripheral intravenous phenytoin administration.

It may present with:

• pain,
• edema,
• bluish-purple discoloration,
• and tissue injury distal to the injection site.

Severe cases may progress to tissue necrosis and ischemia and can occasionally require surgical intervention.

Q3. Why does my doctor order phenytoin blood levels?

Phenytoin has:

• a narrow therapeutic index,
• high protein binding,
• nonlinear metabolism,
• substantial interpatient variability,
• and many drug interactions.

Consequently, relatively small dose changes can sometimes produce large changes in serum concentrations.

Therapeutic drug monitoring helps maintain efficacy while reducing toxicity.

A commonly used total serum therapeutic range is approximately 10–20 mcg/mL, but the clinical situation and, in selected patients, the unbound concentration are more important than relying on the number alone.

Q4. Can I switch from Phenytin capsules to the oral suspension?

Do not switch without medical supervision.

The suspension contains phenytoin free acid, while the capsules contain phenytoin sodium.

Because the free-acid formulation contains approximately 8% more active phenytoin per equivalent labeled amount, switching formulations may alter serum drug concentrations and may require dose adjustment and therapeutic drug monitoring.

Q5. Can phenytoin be stopped suddenly?

No, not without medical supervision.

Abrupt discontinuation may precipitate seizures and potentially status epilepticus.

Q6. Is phenytoin effective for absence seizures?

No.

Phenytoin is not an appropriate treatment for typical absence seizures and may worsen some generalized seizure patterns.

Q7. Why can phenytoin cause gum enlargement?

Long-term phenytoin exposure can cause gingival hyperplasia/gingival overgrowth.

Excellent oral hygiene and regular professional dental care can reduce the severity of this adverse effect.

Q8. Can phenytoin be used during pregnancy?

Sometimes, when clinically necessary.

Pregnancy does not automatically mean that phenytoin must be stopped. However, phenytoin carries fetal risks, while uncontrolled seizures also carry significant risks.

Treatment should therefore be individualized, and serum concentrations may need closer monitoring during pregnancy because pharmacokinetics can change.

Q9. Can a mother taking phenytoin breastfeed?

Phenytoin enters breast milk in relatively small amounts.

Breastfeeding may be possible in many circumstances, but the decision should be individualized and the infant should be monitored for poor feeding, excessive sleepiness, or inadequate weight gain.

Q10. Why is intravenous phenytoin considered high risk?

The injectable formulation can cause serious cardiovascular toxicity, especially when administered too rapidly.

It can also cause severe local tissue injury, including purple glove syndrome.

Therefore, intravenous administration requires appropriate monitoring, controlled administration rates, appropriate dilution when indicated, and careful attention to the injection site.

Q11. What should I do if a rash develops while taking phenytoin?

A new significant rash while taking phenytoin should be treated seriously because phenytoin can cause life-threatening reactions such as SJS, TEN, and DRESS.

Urgent medical assessment is especially important when the rash is associated with fever, mucosal lesions, facial swelling, blistering, skin pain, or systemic symptoms.

Q12. Why should the same phenytoin formulation be maintained?

Phenytoin exposure can change with formulation differences.

In particular, switching between phenytoin sodium and phenytoin free acid formulations may alter the amount of active phenytoin delivered. Current labeling specifically recommends caution and serum-level monitoring when switching formulations.

References

1. U.S. Food and Drug Administration (FDA) — Pharmacogenomic Biomarkers in Drug Labeling, updated December 2025.
2. DailyMed / U.S. National Library of Medicine — Phenytoin Sodium Injection prescribing information, including cardiovascular boxed warning, administration rate, dilution, and monitoring requirements.
3. DailyMed — Current phenytoin oral suspension prescribing information, including dosing, formulation switching, therapeutic monitoring, and renal/hepatic considerations.
4. DailyMed — Current extended phenytoin sodium capsule prescribing information, including formulation switching and special-population considerations.
5. NICE Guideline NG217 — Epilepsies in children, young people and adults, updated January 30, 2025.
6. The NILE Co. for Pharmaceuticals and Chemical Industries — Phenytin historical product information, supplied source document.
7. Historical Phenytin product information and Egyptian registration data contained in the supplied document, including dosage forms, strengths, manufacturer information, packaging, and product codes.

Regulatory Product Codes — Egypt (as listed in the supplied historical document)

• Capsule 50 mg, 50 capsules: 430334
• Capsule 100 mg, 50 capsules: 430337
• Suspension 30 mg/5 mL, 120 mL: 430537
• Ampoule 100 mg/2 mL, 10 ampoules: 431212
• Ampoule 250 mg/5 mL, 10 ampoules: 431213
• Ampoule 250 mg/5 mL, 100 ampoules: 431214

These codes are reproduced from the supplied historical document and should be checked against current Egyptian regulatory records before being presented as current registration information.

Important Editorial Note

The original supplied Phenytin document contains valuable product-specific information, but it is explicitly dated 2/2009.

For that reason, several older statements have deliberately not been reproduced literally where modern prescribing information differs.

The most important updates/corrections include:

• The mechanism is described as voltage-gated sodium-channel blockade, rather than simply "promoting sodium efflux."
• Modern guidance emphasizes individualized dosing and therapeutic drug monitoring rather than relying on a fixed historical regimen.
• Intramuscular phenytoin is generally discouraged because of erratic absorption and local toxicity.
• Intravenous phenytoin must be administered at carefully controlled rates with cardiovascular monitoring.
• D5W/dextrose-containing solutions should be avoided because phenytoin sodium can precipitate.
• The distinction between phenytoin sodium and phenytoin free acid is clinically important, with approximately an 8% difference in phenytoin content between the formulations.
• Renal disease, hepatic disease, and hypoalbuminemia can increase the free active fraction; unbound serum phenytoin may therefore be preferable to total concentration in selected patients.
• Contemporary status-epilepticus guidance places phenytoin among second-line options after benzodiazepines rather than presenting it as the universal first emergency medication.
• The older interaction statement listing vitamin D as a routine agent that increases phenytoin concentration has not been retained as written because the clinically important long-term relationship is more complex and includes phenytoin-associated effects on vitamin-D metabolism and bone health.

The purpose of these corrections is to preserve the useful product-specific information from the original document while avoiding propagation of outdated prescribing information.